Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastati

What happened: Revolution Medicines (Nasdaq: RVMD) said it has begun treating patients in RASolve 308, a global Phase 3 trial of zoldonrasib plus pembrolizumab and platinum-based chemotherapy as first-line treatment for metastatic RAS G12D non-squamous NSCLC. Key numbers: RAS G12D occurs in about 4% of NSCLC cases; RAS mutations Why it matters: The company said initial data on the combination showed encouraging preliminary antitumor activity and a favorable safety profile, providing the rationale for the Phase 3 trial. It noted no targeted therapy is currently approved for these patients. Market: +5.0% today ($191.19), +142.0% YTD, 0.1x vol — as of 14:17 UTC

Revolution Medicines (Nasdaq: RVMD) said it has begun treating patients in RASolve 308, a global Phase 3 trial of zoldonrasib plus pembrolizumab and platinum-based chemotherapy as first-line treatment for metastatic RAS G12D non-squamous NSCLC.

The company said initial data on the combination showed encouraging preliminary antitumor activity and a favorable safety profile, providing the rationale for the Phase 3 trial. It noted no targeted therapy is currently approved for these patients. Market: +5.0% today ($191.19), +142.0% YTD, 0.1x vol — as of 14:17 UTC